Benzinga | Sep 23, 2020 08:05AM EDT

Alimera Sciences Announces Multiple Posters And Papers Highlighting Durability Of ILUVIEN To Be Presented At EURETINA 2020 Virtual Congress

ATLANTA, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that clinical data for ILUVIEN(r) (fluocinolone acetonide intravitreal implant) 0.19mg will be featured in over 20 papers and presentations during the EURETINA 2020 Virtual Congress, to be held on October 2-4, 2020.



Key presentations include data supporting the safety and efficacy of ILUVIEN as a durable three-year continuous delivery system for the treatment of both diabetic macular edema and the prevention of relapse of non-infectious uveitis affecting the posterior segment.

Select ILUVIEN papers include:

Title:"3-year outcomes from the European Registry Safety Study: long-term observational data from patients with DME treated with the 0.19 FAc implant in clinical practice"

Author: Ramin Khoramnia, Associate Professor, Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany

Title:"NIU-PS treated with the FAc implant: a 3-year fellow eye subgroup analysis of the PSV-FAI-001 study"

Author: Carlos Pavesio, Consultant Ophthalmologist, Moorfields Eye Hospital, UK

Title:"UK Real-life long-term outcomes for patients treated with the 0.19 mg FAc implant for DME: 3-year follow-up from the Medisoft Audit Group"

Author: Claire Bailey, Consultant Ophthalmologist, Bristol Eye Hospital, UK